Immunogenicity and Safety Study of GSK Biologicals' Human Papillomavirus 580299 Vaccine in Healthy Female Subjects

Subjects will receive three doses of the Cervarix vaccine intramuscularly according to a 0, 1, 6-month schedule.

Subjects will receive three doses of control intramuscularly according to a 0, 1, 6-month schedule.